Sandoz Canada Aims To Educate On Biosimilars
New Campaign Kicks Off This Week
A dedicated website will spearhead a public education campaign initiated by Sandoz Canada for biosimilars, as their influence and presence continue to grow in the North American market. Sandoz itself is planning a portfolio of five products by the middle of 2021.
You may also be interested in...
The CGPA is drawing attention to the cost savings Canadians can benefit from through the use of generic drugs via a PSA-style digital campaign.
The FDA and FTC have been working on improving information exchange about activities which could undermine biosimilar competition, as well as addressing misinformation about factors such as interchangeability.
Sandoz has launched a global campaign to increase uptake of biosimilars, under the banner of Act4Biosimilars. The initiative aims to increase the adoption of biosimilars by at least 30% in at least 30 countries by 2030.